Alector, INC

Alector announced its second quarter 2026 financial results, reporting $172.8 million in cash and cash equivalents, sufficient to fund operations through 2027, while detailing progress in its Alector Brain Carrier (ABC) platform and related drug candidates.

Alector, Inc. announced the termination of its collaboration agreement with Glaxo Wellcome UK Limited (GSK) and the full repayment of its loan facility with Hercules Capital, Inc.

Alector, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of Class II directors and the ratification of its independent auditor.

Alector, Inc. has entered into a new sales agreement with TD Securities (USA) LLC to offer and sell up to $125 million of its common stock from time to time.

Alector, Inc. announced its fourth quarter and full year 2025 financial results, reporting a significant increase in net loss while advancing its Alector Brain Carrier (ABC) platform and clinical programs.

Alector, Inc. has officially appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025, solidifying his interim role.

Alector, Inc. reported a significant net loss in Q3 2025, discontinued its Phase 3 latozinemab trial, and announced further workforce reductions to realign strategic priorities.

Alector, a late-stage clinical biotechnology company, reported a reduced net loss in Q2 2025, extended its cash runway into H2 2027, and provided updates on its neurodegeneration pipeline, including Phase 3 and Phase 2 trials.

Alector, Inc. announces its Q1 2025 financial results, highlighting progress in clinical trials and strategic pipeline advancements despite a net loss of $40.5 million.

Alector Inc. released its 10-Q filing for the quarter ended September 30, 2024, detailing financial results and providing updates on its clinical programs.

Alector Inc. released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs.

Alector Inc. announced its first quarter 2024 financial results, highlighting progress in clinical trials and a recent public offering.

Alector, a clinical-stage biotechnology company, reported a net loss of $142.9 million in 2025, alongside pipeline advancements for nivisnebart and preclinical programs, and a significant workforce reduction.

Alector's annual report highlights clinical advancements in neurodegenerative disease treatments, strategic collaborations, and financial adjustments for sustained growth.

Alector Inc.'s 10-K filing outlines the company's capital stock structure, including common and preferred stock, and details various provisions that could have anti-takeover effects.

Alector, Inc. reports that Grace Wong-Sarad, Principal Accounting Officer, acquired 20,000 restricted stock units.

Alector, Inc. Director Kristine Yaffe reported transactions involving restricted stock units and stock options on June 17, 2026.

Richard H. Scheller, a Director at Alector, Inc., reported transactions involving the acquisition of common stock and stock options.

Alector, Inc. Director Paula Hammond reported the acquisition of 28,700 shares of common stock through restricted stock units and 9,450 stock options.

Alector, Inc. Director Mark Altmeyer acquired 28,700 shares of common stock through restricted stock units and was granted options for 9,450 shares.

Alector, Inc. Director Errol B. Desouza reported transactions involving restricted stock units and stock options on June 17, 2026.

Alector, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Alector, Inc. announces its annual stockholder meeting to be held virtually on June 12, 2024, to vote on the election of directors, ratification of the appointment of Ernst & Young, LLP, and an advisory vote on executive compensation.

Alector, Inc. will hold its 2025 annual meeting of stockholders virtually on June 11, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and conduct an advisory vote on executive compensation.

Alector, Inc. will hold its annual stockholder meeting virtually on June 12, 2024, to vote on the election of directors, ratification of the appointment of Ernst & Young, LLP, and an advisory vote on executive compensation.

Alector, Inc. has scheduled its 2024 annual meeting of stockholders for June 12, 2024, to address director elections, auditor ratification, executive compensation, and other business matters.

Polaris Venture Partners entities and associated individuals have updated their beneficial ownership filings for Alector, Inc., reflecting holdings as of April 30, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.2% of Alector, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Alector Inc. common stock following an internal realignment.

RTW Investments, LP and Roderick Wong, M.D. have reported 0% beneficial ownership in Alector, Inc., indicating a complete divestment of their previous holdings.

Arnon Rosenthal, a key insider at Alector, Inc., reported beneficial ownership of 7.4% of the company's common stock as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 6.32% beneficial ownership stake in Alector Inc. as of December 31, 2025.